The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it ...

Wegovy-maker Novo Nordisk will cut 9,000 jobs, or about 11.5% of its workforce, in a restructuring to save 8 billion Danish ...

Novo Nordisk said the job cuts will eliminate about 11% of its workforce, with 5,000 of the reductions in Denmark.

The maker of the popular weight-loss drug Wegovy announced on Wednesday that it will be cutting 9,000 jobs in the company.

Novo Nordisk, the Danish pharmaceutical giant behind weight-loss drug Wegovy and diabetes treatment Ozempic, announced plans to cut 9,000 jobs, or 11.5% of its global workforce, as part of a major ...

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals, a healthy balance sheet, and solid management. Recent stock weakness stems from sector-wide regulatory ...

In this article I'll use Charlie Munger's inversion model to analyze Novo Nordisk's potential failure points. We'll go over the recent market share loss, supply chain issues, their R&D pipeline, and ...

The Food and Drug Administration has approved a new indication for Novo Nordisk’s Wegovy (semaglutide) injection 2.4 mg, making it the first and only glucagon-like peptide-1 receptor agonist ...